Role of NUCB2/nesfatin-1 as a possible biomarker

Current Pharmaceutical Design

Volumn 19, Issue 39, 2013, Pages 6986-6992

  Aydin, Suleyman ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Biomarker; Nesfatin 1; Nesfatin nucleobindin 2; NUCB2; Satiety

Indexed keywords

BIOLOGICAL MARKER; NESFATIN 1; NUCB2 PROTEIN; UNCLASSIFIED DRUG;

ANOREXIA NERVOSA; ARTICLE; BODY FLUID; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); GENERALIZED ANXIETY DISORDER; GESTATIONAL AGE; HUMAN; LUNG CANCER; MAJOR DEPRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; DNA-BINDING PROTEINS; HUMANS; NERVE TISSUE PROTEINS;

EID: 84885841630     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281939131127143422     Document Type: Article

References (52)

1. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443(7112): 709-12.
2. Goebel M, Stengel A, Wang L, Taché Y. Central nesfatin-1 reduces the nocturnal food intake in mice by reducing meal size and increasing inter-meal intervals. Peptides 2011; 32(1): 36-43.
3. Yamada M, Horiguchi K, Umezawa R, et al. Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology 2010; 151(6): 2494-503.
4. Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J 2009; 56(4): 537-43.
5. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 2010; 298(6): R1642-7.
6. Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 2011; 22(6): 309-12.
7. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in euroendocrine regulation. J Mol Endocrinol 2010; 45(5): 281-90.
8. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta 2009; 1796(2): 176-93.
9. Aydin S. The presence of the peptides apelin, ghrelin and nesfatin-1 in the human breast milk, and the lowering of their levels in patients with gestational diabetes mellitus. Peptides 2010; 31(12): 2236-40.
10. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in nonobese males. Clin Endocrinol (Oxf) 2010; 73(4): 484-90.
11. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159(1-3): 72-7.
12. Ogiso K, Asakawa A, Amitani H, et al. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 2011; 32(1): 150-3.
13. Aslan M, Celik O, Celik N, et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 2012; 41(3): 424-9.
14. Deniz R, Gurates B, Aydin S, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 2012; 42(33): 694-9.
15. Gunay H, Tutuncu R, Aydin S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012; 37(12): 1949-53.
16. Basar O, Akbal E, Koklu S, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012; 72(6): 479-83.
17. Aydin S, Dag E, Ozkan Y, et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009; 328(1-2): 49-56.
18. Aydin S, Dag E, Ozkan Y, et al. Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients. Peptides 2011; 32(6): 1276-80.
19. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120(2): 91-5.
20. Ghanbari-Niaki A, Kraemer RR, Soltani R. Plasma nesfatin-1 and glucoregulatory hormone responses to two different anaerobic exercise sessions. Eur J Appl Physiol 2010; 110(4): 863-8.
21. Saldanha JF, Carrero JJ, Lobo JC, et al. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Regul Pept 2012; 173(1-3): 82-5.
22. García-Galiano D, Pineda R, Ilhan T, et al. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology 2012; 153(4): 1959-71.
23. Foo KS, Brismar H, Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008; 156(3): 563-79.
24. Gonzalez R, Tiwari A. Unniappan SPancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009; 381(4): 643-8.
25. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204(3): 255-63.
26. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150(1): 232-8.
27. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase database. Nucleic Acids Res 2010; 38(Database issue): D227-33.
28. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2012; 40(Database issue): D343-50.
29. Aydin S. Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors? Ann Hepatol 2012; 11(1): 145-6.
30. Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk J Biochem 2007; 32(2): 76-89.
31. Hosoda H, Doi K, Nagaya N, et al. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem 2004; 50(6): 1077-80.
32. Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clin Endocrinol (Oxf) 2011; 74(3): 325-31.
33. Stengel A, Keire D, Goebel M, et al. The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides. Endocrinology 2009; 150(11): 5113-8.
34. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem 2011; 414(1): 38-46.
35. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85(2): 495-522.
36. Gröschl M, Uhr M, Kraus T. Evaluation of the comparability of commercial ghrelin assays. Clin Chem 2004; 50(2): 457-8.
37. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151(7): 3169-80.
38. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van Hul W. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab 2011; 103(3): 282-6.
39. Zegers D, Beckers S, de Freitas F, et al. Identification of mutations in the NUCB2/nesfatin gene in children with severe obesity. Mol Genet Metab 2012; 107(4): 729-34.
40. Chen YY, Chan RM, Tan KM, et al. The association of a nucleobindin 2 gene (NUCB2) variant with childhood adiposity. Gene 2012; S0378-1119(12): 01524-7.
41. Cetinkaya H, Karagöz B, Bilgi O, et al. Nesfatin-1 in advanced lung cancer patients with weight loss. Regul Pept 2012; S0167-0115(12): 00251-0.
42. Boutsikou T, Briana DD, Boutsikou M, et al. Cord blood nesfatin-1 in large for gestational age pregnancies. Cytokine 2012; S1043-4666(12): 00765-X.
43. Cheng YY, Zhao XM, Cai BP, Ma LN, Yin JY, Song GY. Nesfatin-1 in newborns: relationship with endocrine and metabolic and anthropometric measures. J Pediatr Endocrinol Metab 2012; 25(7-8): 727-32.
44. Celik A, Gurger M, Can C, et al. The Effect of Nesfatin-1 Levels on Paroxysmal Supraventricular Tachycardia. J Investig Med 2013; Article in press.
45. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(2): 497-500.
46. Xu L, Bloem B, Gaszner B, Roubos EW, Kozicz T. Sex-specific effects of fasting on urocortin 1, cocaine-and amphetamineregulated transcript peptide and nesfatin-1 expression in the rat Edinger-Westphal nucleus. Neuroscience 2009; 162(4): 1141-9.
47. Bloem B, Xu L, Morava E, et al. Sex-specific differences in the dynamics of cocaine-and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls. Neuropharmacology 2012; 62(1): 297-303.
48. Gonzalez R, Kerbel B, Chun A, Unniappan S. Molecular, cellular and physiological evidences for the anorexigenic actions of nesfatin-1 in goldfish. PLoS One 2010 3; 5(12): 15201.
49. García-Galiano D, Navarro VM, Roa J, et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci 2010; 30(23): 7783-92.
50. http://www. shibayagi. co. jp/en/pdf/Nesfatin1RevE0511. pdf.
51. Shimizu H, Ohsaki A, Oh-I S, Okada S, Mori M. A new anorexigenic protein, nesfatin-1. Peptides 2009; 30(5): 995-8.
52. Stengel A, Taché Y. Minireview: nesfatin-1-an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology 2011; 152(11): 4033-8.